{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:58:46Z","timestamp":1760608726906},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:p>In this multicenter trial, the effects of nebivolol added to an angiotensin\u2010converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) were assessed in patients with hypertension (diastolic blood pressure [DBP] 80\u2013110\u00a0mm\u00a0Hg) and prediabetes (fasting blood glucose 100\u2013125\u00a0mg\/dL and\/or 2\u2010hour oral glucose tolerance test [OGTT] 140\u2013199\u00a0mg\/dL). After a 4\u2010week run\u2010in period (in which lisinopril [10\u00a0mg\/d] or losartan [50\u00a0mg\/d] treatment was initiated), patients with DBP 90\u2013110\u00a0mm\u00a0Hg were randomized (2:2:1) to 12\u2010week, double\u2010blind treatment with nebivolol (n=223; 5\u201340\u00a0mg\/d), hydrochlorothiazide (HCTZ; n=212; 12.5\u201325\u00a0mg\/d), or placebo (n=102), titrated to achievement of 130\/80\u00a0mm\u00a0Hg. The primary outcome measure was DBP (last observation carried forward, intent to treat population); secondary measures included systolic blood pressure (SBP) and glucose levels. At baseline, overall mean values for body mass index, triglycerides, and high\u2010density lipoprotein cholesterol were 32.3\u00a0kg\/m<jats:sup>2<\/jats:sup>, 1.7\u00a0mmol\/L, and 1.3\u00a0mmol\/L, respectively. At week 12, nebivolol and placebo groups demonstrated a decrease of \u22129.4 and \u22125.0\u00a0mm\u00a0Hg, respectively (<jats:italic>P<\/jats:italic>&lt;.001) for DBP and \u221210.4 and \u22127.8\u00a0mm\u00a0Hg for SBP (<jats:italic>P<\/jats:italic>=.147). The mean changes in area under the curve OGTT were 0.0\u00a0mg\/dL (nebivolol), 6.9\u00a0mg\/dL (HCTZ; <jats:italic>P<\/jats:italic>=.024 vs nebivolol), and \u22121.0\u00a0mg\/dL (placebo). Adverse event\u2013related discontinuation rates were 10.3%, 6.6%, and 2.0%, respectively. Nebivolol, added to an ACE inhibitor or ARB, provides additional blood pressure reduction with little or no effect on glucose metabolism in hypertensive patients with prediabetes.<\/jats:p>","DOI":"10.1111\/jch.12071","type":"journal-article","created":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T20:30:21Z","timestamp":1359750621000},"page":"270-278","source":"Crossref","is-referenced-by-count":23,"title":["Effects of Add\u2010On Nebivolol on Blood Pressure and Glucose Parameters in Hypertensive Patients With Prediabetes"],"prefix":"10.1111","volume":"15","author":[{"given":"Prakash","family":"Deedwania","sequence":"first","affiliation":[{"name":"Department of Medicine UCSF School of Medicine San Francisco CA"},{"name":"Department of Cardiovascular Cardiology section UCSF Program Fresno CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Shea","sequence":"additional","affiliation":[{"name":"Forest Research Institute Jersey City NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Forest Research Institute Jersey City NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Brener","sequence":"additional","affiliation":[{"name":"Forest Research Institute Jersey City NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1296"},{"key":"e_1_2_8_3_1","volume-title":"United States Census Bureau: Population Estimates","year":"2012"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-11-200406010-00035"},{"key":"e_1_2_8_5_1","first-page":"233","volume-title":"Diabetes in America","author":"Geiss LS","year":"1995"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1957"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00835.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.8.1397"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.11.2626"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.010"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1246-y"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685628"},{"issue":"1","key":"e_1_2_8_13_1","first-page":"S65","article-title":"Hypertension management in adults with diabetes","volume":"27","author":"Arauz\u2010Pacheco C","year":"2004","journal-title":"Diabetes Care."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200304000-00024"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.016337"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283469976"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S011"},{"key":"e_1_2_8_20_1","first-page":"1462","article-title":"2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"28","author":"Mancia G","year":"2007","journal-title":"Eur Heart J."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.05.057"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.037"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60108-1"},{"key":"e_1_2_8_24_1","first-page":"6:","article-title":"New\u2010onset diabetes and antihypertensive treatment","volume":"16","author":"Grimm C","year":"2010","journal-title":"GMS Health Technol Assess."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-S042"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903533681"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00454.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.05.066"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487"},{"key":"e_1_2_8_30_1","first-page":"283","article-title":"Placebo\u2010controlled comparison of the effects of nebivolol and low\u2010dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients","volume":"8","author":"Lacourciere Y","year":"1994","journal-title":"J Hum Hypertens."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/7.2.137"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.33"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00666.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00666.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200108000-00011"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000533"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000234121.48272.67"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2006.00718.x"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181eb4ff2"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/107424840300800206"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.189381"},{"key":"e_1_2_8_42_1","first-page":"283","article-title":"Repeated measurements of non\u2010invasive ambulatory blood pressure: distinction between reproducibility and the proper effect of placebo","volume":"1","author":"Asmar R","year":"1996","journal-title":"Blood Press Monit."}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12071","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.12071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T02:02:06Z","timestamp":1698631326000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.12071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/jch.12071"],"URL":"https:\/\/doi.org\/10.1111\/jch.12071","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}